Neural Conduit Agent Dissemination

• US 20070237797A1
• Filed: 04/07/2006
• Published: 10/11/2007
• Est. Priority Date: 03/28/2006
• Status: Abandoned Application

• Current Assignee: Minu, LLC
• Original Assignee: Gholam A. Peyman
• Inventors: Peyman, Gholam
• Application Number:
  US11/278,992
• Publication Number:
  US 20070237797A1
• Time in Patent Office: Days
• US Class Current: 424/400
• CPC Class Codes: A61K 31/7105 Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 31/711 Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 41/0028 Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0043 Nose
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/0085 Brain, e.g. brain implants; Spinal cord
• CPC Class Codes: A61K 9/51 Nanocapsules; Nanoparticles; nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00

Abstract

A method for dissemination of a biocompatible agent using a neural conduit. In one embodiment, agent dissemination is facilitated, for example, by the application of thermal energy, ultrasound energy, radiant energy, electromagnetic energy, or electrical current. As one example, agent may be provided to a sensory organ such as the eye, ear, or nose, for dissemination along the optic nerve to the central nervous system. As another example, agent may be provided at an acupuncture site for dissemination along a peripheral nerve to either a second peripheral nerve site or a central nervous system site.

Claims

1. A method of disseminating a biocompatible agent to a patient, the method comprising providing to a patient in need thereof an agent capable of exerting an effect at a distal neural site, the agent provided by a non-topical ocular route of administration for dissemination via a neural conduit to exert the effect at the distal neural site.

4. The method of claim 1 wherein the distal neural site is a central nervous system site or a non-ocular peripheral nervous system site.

5. The method of claim 1 wherein the route of administration is at least one of intraocular injection or intraocular implantation.

6. The method of claim 1 wherein the agent is disseminated in the perineurium of the optic nerve.

7. The method of any of claim 1, claim 2, or claim 3 wherein dissemination is facilitated by application of at least one of electrical current, ultrasound energy, radiant energy, bioelectromagnetic therapy, or thermal energy.

8. The method of any of claim 1, claim 2, or claim 3 wherein the agent is at least one of a drug, a vaccine, a peptide, a protein, or a vector containing a gene therapy agent.

9. The method of any of claim 1, claim 2, or claim 3 wherein the agent is conjugated to a transport facilitating moiety.

10. The method of any of claim 1, claim 2, or claim 3 wherein the agent is formulated for controlled release.

11. The method of any of claim 1, claim 2, or claim 3 wherein the agent is selected from at least one of a macrolide, anti-prostaglandin, matrix metalloproteinase inhibitor, anti-viral agent, antioxidant, anti-cell migration agent, angiogenic agent, anti-angiogenic agent, or anti-neoplastic agent.

12. The method of any of claim 1, claim 2, or claim 3 wherein the agent is for alleviation of at least one of retinitis pigmentosa, age related macular degeneration, arthritic anterior ischemic optic neuropathy, multiple sclerosis, diabetic retinopathy, scleritis, uveitis, vasculitis, retinoblastoma, choroidal melanoma, pre-malignant and malignant conjunctival melanoma, optic nerve pathologies, Parkinson'"'"'s disease, Alzheimer'"'"'s disease, epilepsy, narcolepsy, seizures, spinal cord injury, or central nervous system pathologies.

13. The method of any of claim 1, claim 2, or claim 3 wherein the agent is formulated as at least one of a solution, suspension, emulsion, microspheres, nanospheres, liposomes, microparticles, or nanoparticles.

2. A method of disseminating a biocompatible agent to a patient, the method comprising providing to a patient in need thereof at a first peripheral nervous system site, an agent capable of exerting via dissemination by a neural conduit an effect at least one of a second peripheral nervous system site or a central nervous system site, the agent administered at least one acupuncture site by at least one of injection, transdermal administration, or facilitated topical administration.

3. A method of disseminating a biocompatible agent to a patient, the method comprising providing to at least one of an oral cavity or a nasal cavity of a patient in need thereof for dissemination via a neural conduit from a Eustachian tube to at least one of a second peripheral nervous system site or a central nervous system site, an agent capable of exerting an effect at the site.

14. A method of disseminating a biocompatible agent, the method comprising providing to an individual at a first neural site an agent selected from the group consisting of an acetylcholinestrase inhibitor, an L-type calcium channel modulator, an agonist of a nicotinic alpha-7 receptor, an inhibitor of phosphodiesterase 10, an inhibitor of phosphodiesterase 4, and combinations thereof, the agent disseminated along a neural conduit to a central nervous system site in need of therapy, the agent administered by at least one of

a non-topical ocular route,

injection, transdermal application, or facilitated topical administration at least one acupuncture site,

administration at an olfactory site, or

pharynx or nasal administration to a Eustachian tube.

15. The method of claim 14 wherein the agent is targeted to a region of the brain.

16. The method of claim 14 wherein administration is facilitated by application of at least one of electrical current, ultrasound energy, radiant energy, bioelectromagnetic therapy, or thermal energy.